The agreements for 2-DG and Molnupiravir contain a complete payment of Rs 8 lakh plus taxes for grant of licences on non-exclusive foundation, Suven Pharma knowledgeable the bourses on Thursday, including that it is a associated social gathering transaction as considered one of its unbiased administrators, Dr S Chandrasekhar, is the director of CSIR-IICT, Hyderabad.
Suven Pharmaceuticals mentioned IICT Hyderabad and National Institute of Interdisciplinary Science & Technology (NIIST), Thiruvananthapuram, each Council of Scientific & Industrial Research (CSIR) institutes, have entered right into a non-exclusive settlement with the corporate for the process know-how switch and manufacturing of anti-influenza drug Molnupiravir, which has been repurposed for Covid-19.
While the artificial process knowhow for Molnupiravir was sourced from CSIR-NIIST, the dimensions up process was carried out by CSIR-IICT. “The complete technology knowhow for Molnupiravir will be transferred and SPL will manufacture and launch it in the domestic market, subject to regulatory approvals,” Suven mentioned.
“Molnupiravir was initially developed for the treatment of influenza and is repurposed to completely suppress the Covid virus transmission within 24 hours according to the study recently published in the journal Nature Microbiology. The drug could be a game changer in mitigation of SARS-CoV-2 virus” Suven Pharma mentioned.
As per the settlement, CSIR IICT would additionally present the process knowhow for the manufacture of latest anti-Covid drug 2-DG.